These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23270198)

  • 1. Treatment of nodular basal cell carcinoma with cryotherapy and reduced protocol of imiquimod.
    Moutran R; Maatouk I; Stephan F; Tomb R
    Cutis; 2012 Nov; 90(5):256-7. PubMed ID: 23270198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of clinical efficacy of imiquimod and cryotherapy for the treatment of basal cell carcinoma with incomplete response to imiquimod.
    Messeguer F; Serra-Guillen C; Echeverria B; Requena C; Sanmartin O; Llombart B; Guillen C; Nagore E
    J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):879-81. PubMed ID: 21752102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryoimmunotherapy: superficial basal cell cancer and squamous cell carcinoma in situ treated with liquid nitrogen followed by imiquimod.
    MacFarlane DF; El Tal AK
    Arch Dermatol; 2011 Nov; 147(11):1326-7. PubMed ID: 22106125
    [No Abstract]   [Full Text] [Related]  

  • 4. Large facial basal cell carcinoma treated with multimodal combination therapy.
    Rubenzik MK; Schwartz LR; Humphreys TR
    Cutis; 2011 Oct; 88(4):182-4. PubMed ID: 22106726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.
    Tillman DK; Carroll MT
    J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s7-14. PubMed ID: 18277457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report.
    Rigel DS; Torres AM; Ely H
    J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s15-6. PubMed ID: 18277458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
    Gaitanis G; Bassukas ID
    Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.
    Wu JK; Oh C; Strutton G; Siller G
    Australas J Dermatol; 2006 Feb; 47(1):46-8. PubMed ID: 16405483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma.
    Spencer JM
    Dermatol Surg; 2006 Jan; 32(1):63-9. PubMed ID: 16393600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative.
    Gaitanis G; Kalogeropoulos CD; Bassukas ID
    Dermatology; 2016; 232(1):17-21. PubMed ID: 26583773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.
    Garcia-Martin E; Idoipe M; Gil LM; Pueyo V; Alfaro J; Pablo LE; Zubiri ML; Fernandez J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):373-9. PubMed ID: 20698800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple superficial basal cell carcinomata--topical imiquimod versus curette and cryotherapy.
    Dixon AJ
    Aust Fam Physician; 2005; 34(1-2):49-52. PubMed ID: 15727358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas.
    Berman B
    J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s3-6. PubMed ID: 18277456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
    Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
    J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream.
    Devirgiliis V; Panasiti V; Curzio M; Gobbi S; Rossi M; Roberti V; Calvieri S
    Dermatol Online J; 2008 Feb; 14(2):25. PubMed ID: 18700128
    [No Abstract]   [Full Text] [Related]  

  • 17. Resolution of tinea pedis with imiquimod cream 5% in a patient with nodular basal cell carcinoma.
    Stashower ME
    Cutis; 2006 Jul; 78(1):66-9. PubMed ID: 16903324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of various types of basal cell carcinoma with topical 5% imiquimod in the elderly who refused surgical intervention: a case series.
    Kaçar SD; Özuğuz P; Erkan F; Karaca Ş
    J Dermatolog Treat; 2015 Apr; 26(2):165-7. PubMed ID: 24731081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facial extensive recurrent basal cell carcinoma: successful treatment with photodynamic therapy and imiquimod 5% cream.
    Requena C; Messeguer F; Llombart B; Serra-Guillén C; Guillén C
    Int J Dermatol; 2012 Apr; 51(4):451-4. PubMed ID: 22435437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent invasive basal cell carcinoma after radiation and imiquimod: a case report.
    Wagamon K; Li LJ
    Dermatol Surg; 2007 Jan; 33(1):117-9. PubMed ID: 17214692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.